FINWIRES · TerminalLIVE
FINWIRES

$AZN

59 stories mentioning AZNUpdated just now

Every FINWIRES story that references AZN, newest first.

Wire

AstraZeneca's Durvalumab Approved by FDA in Combination With BCG for Bladder Cancer

Astrazeneca's (AZN) durvalumab, in combination with Bacillus Calmette-Guerin, received approval by the Food and Drug Administration to treat adults with BCG-naive, high-risk non-muscle invasive bladder cancer, the FDA said Thursday.Durvalumab's efficacy was evaluated in the Potomac study, a randomized, open-label, multi-center trial of 1,018 patients with high-risk NMIBC following transurethral resection of bladder tumor, according to the statement.A statistically significant improvement in disease-free survival was observed with durvalumab plus BCG induction and maintenance compared with BCG induction and maintenance alone.The recommended durvalumab dose for patients weighing at least 30 kilograms is 1,500 mg every four weeks for 13 cycles, in combination with BCG induction and maintenance treatment. Treatment should continue until disease recurrence, progression, unacceptable toxicity, or a maximum of 13 cycles.Price: $184.89, Change: $-0.77, Percent Change: -0.41%

$AZN
Asia Markets

Fresh Military Strikes Between US, Iran Drag US Equity Futures Pre-Bell

US equity futures were edging lower pre-bell Thursday as fresh US and Iranian strikes once again threatened the fragile ceasefire between the two nations, reducing optimism surrounding a potential peace deal.Dow Jones Industrial Average futures were 0.3% lower, S&P 500 futures were down 0.1%, and Nasdaq futures were 0.2% lower.The US military said it had fired on Iranian drones over the Strait of Hormuz and attacked a military site in the port city of Bandar Abbas, which is the second time in three days it has struck targets in Iran for what it called self-defense. Iran said it responded by launching an attack on an American air base in the region.Traders observed the latest round of earnings, including those of several major Canadian banks. Royal Bank of Canada (RY) reported higher fiscal Q2 adjusted earnings and revenue, while Toronto-Dominion Bank (TD) posted increased fiscal Q2 adjusted earnings amid lower revenue.Oil prices were higher, with front-month global benchmark North Sea Brent crude up 2.2% at $94.26 per barrel and US West Texas Intermediate crude 2.4% higher at $90.73 per barrel.The April core personal consumption expenditures price index, the Federal Reserve's preferred inflation gauge, released at 8:30 am ET, gained 0.2%, lower than the 0.3% increase in the prior month and the expected 0.3% gain in a survey compiled by Bloomberg.Initial jobless claims rose to 215,000 in the week ended May 23 from 210,000 level in the previous week, compared with expectations for a smaller increase to 211,000. Preliminary Q1 GDP growth was recorded at a 1.6% rise, compared with the advance estimate of a 2% increase.Durable goods new orders rose 7.9% in April after a 1.3% gain in the prior month, compared with expectations for a 4% increase.In other world markets, Japan's Nikkei closed 0.5% lower, Hong Kong's Hang Seng ended 1.3% lower, and China's Shanghai Composite finished 0.1% higher. Meanwhile, the UK's FTSE 100 was down 1%, and Germany's DAX index was 0.7% lower in Europe's early afternoon session.In equities, Dell Technologies (DELL) shares were up 4.6% after the company said its unit Dell Federal Systems won a blanket purchase agreement with an overall estimated value of $9.69 billion from the US Navy under the Department of Defense Enterprise Software Initiative. Snowflake (SNOW) stock was 37% higher after the cloud-based data platform lifted its fiscal 2027 product revenue outlook and agreed to a $6 billion infrastructure spending deal with Amazon's (AMZN) Amazon Web Services. Royal Bank of Canada shares were up 1.7% after the bank reported its fiscal Q2 financial results.On the losing side, HSBC (HSBC) stock was down 2.2% after a Bloomberg News report that UK's Cambridge University was withdrawing its investments from institutions providing financial support to fossil fuels, including the British bank. AstraZeneca (AZN) shares were 0.8% lower after the company said that the US Food and Drug Administration delayed the decision deadline for its new drug application regarding a combination breast cancer treatment.

Dow JonesNasdaq CompositeS&P 500$AMZN$AZN$DELL$HSBC$RY$SNOW$TD
Wire

AstraZeneca, Daiichi Sankyo Win US FDA Approval for Datroway to Treat Triple-Negative Breast Cancer

AstraZeneca (AZN) and Daiichi Sankyo said Friday that the US Food and Drug Administration has approved Datroway for first-line treatment of adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.The approval followed the FDA's priority review based on phase 3 data showing Datroway, or datopotamab deruxtecan, improved median overall survival to 23.7 months compared with 18.7 months for patients treated with chemotherapy, the companies said.Datroway also reduced the risk of disease progression or death by 43%, with median progression-free survival of 10.8 months versus 5.6 months for chemotherapy, according to the companies.The safety profile of Datroway was evaluated in 319 patients, with serious adverse reactions including pneumonia, vomiting, COVID-19 and anemia reported in more than 1% of patients, while one fatality was linked to interstitial lung disease or pneumonitis, Daiichi Sankyo said.Datroway is a TROP2-directed antibody drug conjugate discovered by Daiichi Sankyo and jointly developed and commercialized with AstraZeneca.Shares of AstraZeneca were down 1.4% in Friday trading.Price: $187.16, Change: $-2.59, Percent Change: -1.36%

$AZN
Research

Research Alert: CFRA Adds Shares Of Astrazeneca Plc To The Total Return Portfolio

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We add shares of AstraZeneca Plc (AZN) to the Total Return portfolio, replacing Medtronic (MDT). In our view, AZN's pipeline, one of the strongest vs. peers, provides a compelling long-term growth story. Late-stage pipeline execution remains robust, with four positive high-value Phase 3 readouts and 14 regulatory approvals achieved so far in 2026. More than 20 Phase 3 trial readouts are expected in 2026, offering multiple near-term catalysts. We think the near-term patent expirations (Farxiga, April 2026, and Soliris, 2027) are well-managed through a robust pipeline and successful lifecycle management. In our view, the solid oncology segment remains a primary growth contributor. AZN has built a strong oncology portfolio, with key drugs like Enhertu, Tagrisso, and Imfinzi that are protected well into the 2030s. Q1 2026 demonstrated sustained momentum, with the oncology segment leading revenue growth (+16% CER, with Enhertu +34% CER based on continued global demand).

$AZN
Wire

Top Midday Stories: NextEra, Dominion to Combine in All-Stock Deal; Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

The Dow Jones Industrial Average, Nasdaq Composite and S&P 500 Index were down in late-morning trading Monday, as Wall Street monitored oil prices and US Treasury yields amid the ongoing conflict in the Middle East.In company news, NextEra Energy (NEE) and Dominion Energy (D) said Monday they have entered into a definitive agreement to combine in an all-stock deal. Under the terms of the transaction, Dominion shareholders will receive a fixed exchange ratio of 0.8138 shares of NextEra for each Dominion share they own at the close of the deal, which is expected in the next 12 to 18 months. NextEra shareholders will own about 74.5% of the combined company, while Dominion shareholders will own the remaining 25.5%. NextEra shares were down 5.5% around midday, while Dominion shares were up 9.6%.The US Supreme Court on Monday denied writ of certiorari petitions by six big pharmaceutical companies seeking to challenge the legality of the Medicare Drug Price Negotiation Program under the Inflation Reduction Act of 2022. AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson & Johnson's (JNJ) Janssen Pharmaceuticals, Bristol-Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court. Shares of AstraZeneca, Novartis, Johnson & Johnson and Bristol-Myers were up 1.1%, 0.8%, 0.4% and 0.5%, respectively, while Novo Nordisk was down 1%.Berkshire Hathaway (BRK.A, BRK.B) disclosed Friday in a regulatory filing that it sold all of its stake in UnitedHealth Group (UNH). Separately, a New York state court judge on Monday prohibited prosecutors from using some evidence found in the backpack of Luigi Mangione, who is standing trial for the murder of UnitedHealth Group's UnitedHealthcare CEO Brian Thompson, CNBC reported. UnitedHealth shares were down 1.5%, while Berkshire's class A and class B shares were up 0.2% and 0.1%, respectively.Citigroup (C) and BlackRock's (BLK) HPS Investment Partners are launching a 15 billion euro ($17.48 billion) private capital program to expand access to private financing for corporate and sponsor-owned borrowers in the Europe, the Middle East and Africa region, the companies said Monday. Citigroup shares were down 0.2%, while BlackRock shares were up 0.5%.Price: $88.24, Change: $-5.13, Percent Change: -5.49%

$AZN$BLK$BMY$BRK.A$BRK.B$C$D$JNJ$NEE$NVO$NVS$UNH
Wire

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

The US Supreme Court on Monday denied petitions for writs of certiorari filed by six big pharmaceutical companies seeking to challenge the legality of the so-called 'Drug Price Negotiation Program' under the Inflation Reduction Act of 2022.AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson & Johnson's (JNJ) Janssen Pharmaceuticals, Bristol Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court.The companies did not immediately respond to requests for comment from.Price: $183.25, Change: $+1.67, Percent Change: +0.92%

$AZN$BMY$JNJ$NVO$NVS
Wire

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case

$AZN$BMY$JNJ$NVO$NVS
Asia Markets

European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading

European equities traded in the US as American depositary receipts were moving higher late Thursday morning, rising 0.43% to 1,852.92 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and 3D printer company Materialise (MTLS), which climbed 11.4% and 10.4% respectively. They were followed by lender ING Group (ING) and biopharmaceutical company Cellectis (CLLS), which increased 2.3% and 2.1% respectively.The decliners from continental Europe were led by pharmaceutical company Novo Nordisk (NVO) and internet browser company Opera (OPRA), which fell 1.7% and 1.6% respectively. They were followed by oil and gas company Eni (E) and lender Banco Santander (SAN), which were off 1.3% and 0.5% respectively.The gainers from the UK were led by biopharmaceutical companies NuCana (NCNA) and Akari Therapeutics (AKTX), which advanced 9.6% and 3.2% respectively. They were followed by communications company WPP (WPP) and lender Barclays (BCS), which were up 2.8% and 2.4% respectively.The decliners from the UK and Ireland were led by biotech firm Autolus Therapeutics (AUTL) and mining company BHP Group (BHP), which dropped 9.9% and 2.1% respectively. They were followed by biopharmaceutical company Amarin (AMRN) and pharmaceutical company AstraZeneca (AZN), which were down 1.3% each.

$AKTX$AMRN$AUTL$AZN$BCS$BHP$CLLS$E$ING$MTLS$NCNA$NVO$OPRA$SAN$SQNS$WPP
Wire

Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug

The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN
Wire

AstraZeneca's Breast Cancer Drug Rejected by FDA on Safety Concerns, Bloomberg Reports

AstraZeneca's Breast Cancer Drug Rejected by FDA on Safety Concerns, Bloomberg Reports

$AZN
Sectors

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 1.5%.In corporate news, Boston Scientific (BSX) shares fell 3.3% after Daiwa Securities downgraded the stock to neutral from outperform, and lowered its price target to $60 per share from $83 earlier.AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected Q1 results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs. Its shares rose 3.7%.AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported. AstraZeneca shares were down 1.1%.KalVista Pharmaceuticals (KALV) and Chiesi Group said Wednesday they have signed an agreement through which Chiesi will buy KalVista for $27 per share in cash, or about $1.9 billion. KalVista shares surged 38%.

$ABBV$AZN$BSX$KALV
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index down 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 2%.In corporate news, AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected Q1 results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs. Its shares rose 3.4%.AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported. AstraZeneca shares were down 1.2%.KalVista Pharmaceuticals (KALV) and Chiesi Group said Wednesday they have signed an agreement through which Chiesi will buy KalVista for $27 per share in cash, or about $1.9 billion. KalVista shares surged nearly 39%.

$ABBV$AZN$KALV
Wire

Market Chatter: AstraZeneca to Invest $405 Million in UK Sites

AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported Wednesday.The investment will fund expansion at AstraZeneca's Cambridge biomedical campus and boost manufacturing and research capabilities at its Macclesfield site, according to the report.In a statement to, AstraZeneca CEO Pascal Soriot praised the UK government for its efforts to "improve access for patients, including four new approvals since the beginning of the year across the UK." He said the company is looking forward to "further enhancing the access and the reimbursement environment and build a strong life sciences sector."Soriot said AstraZeneca is "investing a total of 300 million pounds in the UK, which includes investment in our Macclesfield site, including a lab of the future that will use digital and data tools to advance drug development."Shares of AstraZeneca were down 2.3% in US trading on Wednesday.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $183.67, Change: $-3.07, Percent Change: -1.64%

$AZN
Sectors

Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday

Health care stocks were mixed pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) up 0.1%.Teva Pharmaceutical Industries (TEVA) shares were up more than 8% after the company posted higher Q1 non-GAAP earnings and net revenue.AstraZeneca (AZN) stock was down more than 1% even after the company reported higher Q1 core earnings and revenue.GE Healthcare Technologies (GEHC) shares were down more than 9% after the company posted a decline in Q1 adjusted earnings, and cut its 2026 adjusted EPS outlook.

$AZN$GEHC$IBB$TEVA$XLV
Research

Research Alert: Azn Q1 2026 Beat As Oncology Remains Strong; Reaffirms 2026 Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:AstraZeneca (AZN) posted 13% total revenue growth (+8% at constant exchange rates, CER) to USD15.3B in Q1 2026, beating consensus estimates of USD14.9B, with oncology remaining the key contributor (+16% CER). Imfinzi climbed 30% CER, supported by multiple new launches, while Enhertu grew 34% CER on continued global demand, with core operating margin remaining broadly stable Y/Y at 35% despite R&D (+8% CER) and SG&A (+7% CER) expense increases. We continue to like AZN for its strong pipeline and numerous key data readouts throughout 2026, supported by four positive Phase 3 trials and 14 regulatory approvals achieved since Q4 2025. AZN reiterated its 2026 guidance for mid- to high-single-digit revenue growth and low double-digit core EPS growth, with currency movements expected to provide modest support. We see this compelling dataset helping support its ambitious target to reach USD80B in total revenue by 2030, with guidance that is more favorable than peers like Novartis.

$AZN
Sectors

Sector Update: Health Care Stocks Lean Lower Premarket Monday

Health care stocks were leaning lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.4% and the iShares Biotechnology ETF (IBB) down 0.5%.Biogen (BIIB) has agreed to acquire TJ Biopharma's rights to the felzartamab antibody in the Greater China Region under a definitive agreement, the companies said. Biogen shares were up more than 1% pre-bell.AstraZeneca (AZN) said its pivotal phase 3 study of tozorakimab demonstrated a "significant" reduction in the annual rate of moderate-to-severe chronic obstructive pulmonary disease, or COPD, exacerbations in trial participants. Shares of AstraZeneca were down more than 1% premarket.ANI Pharmaceuticals (ANIP) stock was up more than 1% after the company said it has received US Food and Drug Administration approval and launched Pimozide Tablets in 1 mg and 2 mg doses, the generic version of Orap, with 180-day Competitive Generic Therapy exclusivity.

$ANIP$AZN$BIIB$IBB$XLV
Commodities

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Oil Prices Rise on Renewed Middle East Tensions

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.4% lower in Monday's premarket activity as rising oil prices tied to renewed Middle East tensions weigh on sentiment.US stock futures were also lower, with S&P 500 Index futures down 0.5%, Dow Jones Industrial Average futures slipping 0.5%, and Nasdaq futures retreating 0.4% before the start of regular trading.No economic releases are on Monday's schedule.In premarket activity, bitcoin was up by 0.4%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2.8% lower, Ether ETF (EETH) fell by 4.8%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 1.7%.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 0.2%, while the Vanguard Industrials Index Fund (VIS) fell 1.6% and the iShares US Industrials ETF (IYJ) was inactive.TopBuild (BLD) stock was up more than 2% before the opening bell, while QXO (QXO) shares declined by 2% after QXO agreed to acquire TopBuild for $505 per share in a deal valued at about $17 billion.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 0.5%, and the iShares US Technology ETF (IYW) was 0.3% lower, while the iShares Expanded Tech Sector ETF (IGM) was down 0.9%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 0.1% lower, while the iShares Semiconductor ETF (SOXX) decreased by 0.2%.AST SpaceMobile (ASTS) shares were down more than 12% in Monday's premarket activity after the company said Sunday the BlueBird 7 satellite was placed into a lower-than-planned orbit during the New Glenn 3 mission and will be de-orbited.Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated 0.3%, the Vanguard Health Care Index Fund (VHT) retreated 0.4%, while the iShares US Healthcare ETF (IYH) gained 0.1%. The iShares Biotechnology ETF (IBB) was down 0.6%.AstraZeneca (AZN) stock was down more than 2% premarket, after a 2.2% gain at Friday's close. The company said Monday its pivotal phase 3 study of tozorakimab demonstrated a "significant" reduction in the annual rate of moderate-to-severe COPD exacerbations in trial participants.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated 0.5%. Direxion Daily Financial Bull 3X Shares (FAS) was down 1.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.7% higher.Bank of Hawaii (BOH) shares were down more than 2% pre-bell after the company reported lower-than-expected Q1 earnings and revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.2%, while the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 1.1%. The iShares US Consumer Staples ETF (IYK) rose 2.3%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.7%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) retreated by 0.5%.Toyota Motor (TM) shares were down more than 1% pre-bell, after closing Friday with a 2% rise. Reuters reported Monday that Toyota Tsusho and Indonesian state energy firm Pertamina's renewable energy unit are in talks over a potential $200 million to $300 million joint investment for a bioethanol production facility in Indonesia's Lampung province.EnergyThe iShares US Energy ETF (IYE) was 1.3% higher, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 1.1%.Eni (E) stock was up more than 1% before the opening bell after the company said it made a gas discovery in the Kutei Basin off the coast of Indonesia.CommoditiesFront-month US West Texas Intermediate crude oil rose by 5.6% to $88.52 per barrel on the New York Mercantile Exchange. Natural gas advanced by 2.1% to $2.73 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 4.9%, while the United States Natural Gas Fund (UNG) was 1.1% higher.Gold futures for May were down by 1% at $4,830.50 an ounce on the Comex. Silver futures retreated by 2.4% to $80.47 an ounce. SPDR Gold Shares (GLD) was 0.9% lower, and the iShares Silver Trust (SLV) fell by 2%.

Dow JonesNasdaq CompositeS&P 500$ASTS$AZN$BETH$BITO$BLD$BOH$E$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$PMR$QQQ$QXO$RTH$SLV$SOXX$SPY$TM$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Wire

AIM ImmunoTech Starts Late-Stage Trial of Ampligen in Pancreatic Cancer

AIM ImmunoTech (AIM) said Thursday it has begun a phase 3 clinical trial of its experimental drug Ampligen for pancreatic cancer, calling the move an important milestone supported by encouraging phase 2 results.The company recently signed an agreement with Thermo Fisher Scientific's (TMO) PPD clinical research unit to help design the phase 3 study.An ongoing phase 2 trial testing Ampligen with AstraZeneca's (AZN) immunotherapy durvalumab has shown early signs of improved progression-free survival and overall survival, along with a favorable safety profile, AIM said.Price: $0.57, Change: $+0.03, Percent Change: +5.35%

$AIM$AZN$TMO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Trending Lower in Wednesday Trading

European equities traded in the US as American depositary receipts were heading lower late Wednesday morning, declining 0.54% to 1,835.78 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical firm Grifols (GRFS), which advanced 3% and 2.6%, respectively. They were followed by software company SAP (SAP) and biopharmaceutical company argenx (ARGX), which increased 2.5% each.The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and telecommunications company Nokia (NOK), which dropped 4.2% and 1.6%, respectively. They were followed by telecommunications company Ericsson (ERIC) and petroleum refiner Equinor (EQNR), which lost 1.5% and 1.2%, respectively.The gainers from the UK were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and software company Endava (DAVA), which rose 3.2% each. They were followed by biopharmaceutical companies Amarin (AMRN) and NuCana (NCNA), which were up 3% and 2.3% respectively.The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Mereo BioPharma Group (MREO), which fell 2.9% and 2.6% respectively. They were followed by pharmaceutical company AstraZeneca (AZN) and utilities company National Grid (NGG), which were down 1.3% and 1.2% respectively.

$AMRN$ARGX$AZN$DAVCA$EDAP$EQNR$ERIC$GRFS$MREO$NCNA$NGG$NOK$NTZ$SAP$TRIB$VDRZ

Showing 41-59 of 59

Track with the FINWIRES app suite

FolioX
FolioX
Track AZN in your portfolio
WheelAI
WheelAI
Analyze AZN options with the wheel strategy
StockInsider
StockInsider
See market sentiment on AZN